Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05336240 · ClinicalTrials.gov registry record · NA
PCOM2 - The Physician Communication Intervention, Version 2.0
A NA study of HPV Infection and Preventive Health Services, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 2
- Study locations
NCT05336240: Recruiting NA study of HPV Infection and Preventive Health Services, sponsored by University of Colorado, Denver.
NCT05336240 is a NA study of HPV Infection and Preventive Health Services that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 120 participants, below the 227-participant average among 13 other HPV Infection trials with a reported enrollment target (47% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05336240, a NA study of HPV Infection and Preventive Health Services, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 2
- Study locations
Study Summary
Poor quality of primary care providers' vaccine recommendations lead to low adolescent human papillomavirus vaccination rates and hundreds of thousands of adolescents unnecessarily at risk for HPV-associated cancers and diseases. Though a previous provider communication intervention, called PCOM, was found to be effective for increasing adolescent HPV vaccination in primary care, its dissemination is limited by the need for significant research team involvement to teach providers how to use the intervention's components. To address this, investigators propose to develop and test a virtual version of PCOM, use mixed methods to assess contextual factors affecting its use compared to the original PCOM intervention, and develop an optimized version of PCOM for broad dissemination to increase adolescent HPV vaccination nationally.
Primary Outcome
The primary outcome to be assessed in the trial is HPV vaccine series initiation among 11-12-year-olds as 11-12 year-olds are the preferred target population for HPV vaccination and the PCOM intervention had its strongest effect on series initiation rather than completion.
Conditions Studied
Interventions
- BEHAVIORAL Physician Communication 2 Virtual (PCOM2-virtual)
- BEHAVIORAL Physician Communication Standard (PCOM-standard)
Study Locations (2)
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Kansas
- University of Kansas Medical Center - Wichita
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2023-11-15 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What NCT05336240 shows while recruiting
NCT05336240 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 227-participant average among 13 other HPV Infection trials with a reported enrollment target (47% lower).
The record links to 2 conditions, with HPV Infection appearing as the primary indexed condition, and to 2 interventions - of which Physician Communication 2 Virtual (PCOM2-virtual) is the first listed.
NCT05336240 reports a single indexed study location in Colorado, Kansas.
Frequently Asked Questions
What is clinical trial NCT05336240 about?
NCT05336240 is a clinical study titled "PCOM2 - The Physician Communication Intervention, Version 2.0". Poor quality of primary care providers' vaccine recommendations lead to low adolescent human papillomavirus vaccination rates and hundreds of thousands of adolescents unnecessarily at risk for HPV-associated cancers and diseases. Though a previous provider communication intervention, called PCOM, wa...
What is the current status of trial NCT05336240?
This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2023-11-15. Estimated completion is 2026-12-31.
What conditions does trial NCT05336240 study?
This clinical trial studies the following conditions: HPV Infection, Preventive Health Services.
What interventions are being tested in trial NCT05336240?
The interventions under investigation include: Physician Communication 2 Virtual (PCOM2-virtual) (BEHAVIORAL), Physician Communication Standard (PCOM-standard) (BEHAVIORAL).
Who is sponsoring clinical trial NCT05336240?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05336240 being conducted?
This trial has 2 study locations across Colorado, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HPV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05336240's enrollment target sits among peer trials
120 7th of 13 higher than 6 of 13 other HPV Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HPV Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PopSci CHW4CervixHealth
RECRUITING · NA
-
Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer
RECRUITING · NA
-
Game-Based Intervention to Promote HPV Vaccination
ACTIVE NOT RECRUITING · NA
-
SELF-CERV Pivotal Study: SELF-Collection for CERVical Cancer Screening
ACTIVE NOT RECRUITING · NA
-
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
RECRUITING · Phase 4
-
Feasibility of HPV Testing With Mail-delivered Sample Collection Kits
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI